Accretion Nutraveda IPO Overview
Accretion Nutraveda Limited is an Ayurvedic & nutraceutical products manufacturer and Contract Development & Manufacturing Organization (CDMO) based in Sanand, Ahmedabad, Gujarat. The company blends traditional Ayurvedic formulations with modern nutraceutical science, producing tablets, capsules, syrups, powders, oils and external preparations like creams, balms and gels. It serves both domestic markets and overseas clients (Sri Lanka, Singapore, USA).
The company is launching its SME IPO on the BSE SME platform to raise ₹24.77 crore through a 100% fresh issue at a price band of ₹122 – ₹129 per share. The IPO opens on 27–28 January 2026 and is expected to list around 4 February 2026. Retail investors face a relatively higher SME ticket size with minimum 2,000 shares per application (~₹2.58 lakh).
IPO DETAILED INFORMATION
Issue Details
| Parameter | Details |
| IPO Type | SME |
| IPO Open Date | 27–28 January 2026 |
| IPO Close Date | 30 January 2026 |
| Allotment Date | 2 February 2026 (Expected) |
| Credit to Demat | 3 February 2026 (Expected) |
| Refund Initiation | 3 February 2026 (Expected) |
| Listing Date | 4 February 2026 (Tentative) |
| Price Band | ₹122 to ₹129 per share |
| Face Value | ₹10 per share |
| Lot Size | 1,000 shares |
| Min Investment (Retail) | ₹2,58,000 (2 lots = 2,000 shares) |
| sNII Investment | ~₹3,87,000+ (3 lots) |
| bNII Investment | ~₹10,32,000+ (8 lots) |
| Issue Size | ~₹24.77 cr |
| Fresh Issue | ₹24.77 cr (100%) |
| Offer For Sale (OFS) | Nil |
| Total Shares Offered | 19,20,000 equity shares |
| Listing | BSE SME |
Issue Break-up
Approximate allocation structure:
| Category | Allocation | Shares |
| QIB (Qualified Institutional Buyers) | ~47.29% | 9,08,000 |
| NII (Non-Institutional Investors) | ~14.38% | 2,76,000 |
| Retail Individual Investors | ~33.33% | 6,40,000 |
| Market Maker | ~5.00% | 96,000 |
| Total | 100% | 19,20,000 |
Selling Shareholders (OFS)
No Offer for Sale (OFS) – the entire IPO is a fresh issue, and all proceeds go to the company for growth and expansion purposes.
Objects of the Issue (Fund Utilization)
The net proceeds from the IPO will be used for:
- Automation of existing manufacturing machinery – expanding production efficiency.
- Purchase of machinery for a new manufacturing setup – capacity expansion.
- Working capital requirements – supporting operations and order fulfilment.
- General corporate purposes – other strategic needs.
Strategic Context:
- Modernizing and expanding manufacturing aims to capture greater market share in nutraceutical and Ayurvedic product segments.
- Working capital funding is crucial as the company scales exports and diversified product lines.
Lead Managers & Registrar
- Book Running Lead Manager (BRLM): Sobhagya Capital Options Pvt. Ltd.
- Registrar to the Issue: KFin Technologies Ltd.
Promoters & Management
Accretion Nutraveda’s promoters include:
- Mayur Popatlal Sojitra
- Ankurkumar Shantilal Patel
- Paraskumar Vinubhai Parmar
- Hardik Mukundbhai Prajapati
- Harshad Nanubhai Rathod
- Vivek Ashok Kumar Patel
These individuals lead the company’s strategic and operational activities.
COMPANY DETAILS
Accretion Nutraveda Limited was incorporated in 2021 and later converted into a public limited company ahead of the IPO. It operates a GMP & WHO-GMP certified manufacturing facility in Sanand, Gujarat, spanning around 10,763 sq. ft., equipped with overhead air handling systems and processed in controlled environments.
Business Activities:
- Contract development & manufacturing of Ayurvedic and nutraceutical products in multiple dosage formats (tablets, capsules, powders, syrups, oils, balms, creams).
- Domestic sales, merchant exports and direct exports (Sri Lanka, Singapore, USA).
- Focus on health categories like liver care, women’s health, bone & joint support, cognitive & respiratory wellness.
Company Strengths
- Diversified Ayurvedic & nutraceutical product portfolio across multiple dosage forms, enabling broader market reach.
- CDMO model with repeat domestic and export customers beyond India.
- Multiple quality certifications (GMP, WHO-GMP, FSSC 22000, ISO, Halal) enhancing global compliance.
- Revenue growth trajectory from ₹3.07 cr (FY23) to ₹16.06 cr (FY25).
- Experienced promoter management team with hands-on industry exposure.
- Export footprint to Sri Lanka, Singapore and the USA providing geographic diversification.
- Scalable manufacturing with planned automation and new setup.
Key Risks & Challenges
- Highly competitive Ayurvedic & nutraceutical market with established players.
- SME listing volatility and higher minimum investment may reduce retail participation.
- Regulatory risks in healthcare and herbal products segments.
- Lease-based facility may face cost or tenancy risks versus owned assets.
- Sustainability of rapid growth and maintaining high margins over time.
Disclaimer
This document is for informational and educational purposes only and does not constitute investment advice. Investors should read the Red Herring Prospectus (RHP) and consult certified financial advisors before making investment decisions. Past performance is not indicative of future results and investments are subject to market risks.
